CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 40 filers reported holding CTI BIOPHARMA CORP in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $28,000 | -72.3% | 6,669 | -60.0% | 0.00% | – |
| Q4 2022 | $101,000 | +320.8% | 16,685 | +295.9% | 0.00% | – |
| Q3 2022 | $24,000 | +700.0% | 4,214 | +644.5% | 0.00% | – |
| Q2 2022 | $3,000 | – | 566 | +1216.3% | 0.00% | – |
| Q1 2022 | $0 | – | 43 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 43 | -6.5% | 0.00% | – |
| Q3 2021 | $0 | – | 46 | +7.0% | 0.00% | – |
| Q2 2021 | $0 | – | 43 | 0.0% | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 43 | -80.9% | 0.00% | – |
| Q4 2020 | $1,000 | – | 225 | +3.2% | 0.00% | – |
| Q3 2020 | $0 | – | 218 | +407.0% | 0.00% | – |
| Q2 2020 | $0 | – | 43 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 43 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 43 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 43 | -95.8% | 0.00% | – |
| Q3 2018 | $2,000 | +100.0% | 1,024 | +894.2% | 0.00% | – |
| Q2 2018 | $1,000 | – | 103 | +157.5% | 0.00% | – |
| Q4 2017 | $0 | – | 40 | +122.2% | 0.00% | – |
| Q3 2017 | $0 | – | 18 | +100.0% | 0.00% | – |
| Q1 2017 | $0 | – | 9 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 8,800,358 | $21,825,000 | 10.02% |
| CAXTON CORP | 2,239,300 | $5,553,000 | 4.54% |
| Altium Capital Management LP | 2,185,000 | $5,419,000 | 1.49% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,483,829 | $3,680,000 | 1.49% |
| Ghost Tree Capital, LLC | 1,200,000 | $2,976,000 | 1.07% |
| Lion Point Capital, LP | 1,223,595 | $3,034,000 | 0.81% |
| BVF INC/IL | 8,929,690 | $22,146,000 | 0.80% |
| NEA Management Company, LLC | 7,140,450 | $17,708,000 | 0.36% |
| Knott David M Jr | 221,079 | $548,000 | 0.19% |
| Lakeside Advisors, INC. | 97,780 | $242,000 | 0.18% |